Clinical development of SpikoGen®, an Advax-CpG55.2 adjuvanted recombinant spike protein vaccine

References

• Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2020;19(3):1–11. doi:10.1038/s41579-020-00459-7.
   Web of Science ®Google Scholar
• Gu J, Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol. 2007;170(4):1136–47. doi:10.2353/ajpath.2007.061088.
   PubMed Web of Science ®Google Scholar
• Jeworowski LM, Muhlemann B, Walper F, Schmidt ML, Jansen J, Krumbholz A, Simon-Lorière E, Jones TC, Corman VM, Drosten C. Humoral immune escape by current SARS-CoV-2 variants BA.2.86 and JN.1, December 2023. Euro Surveill. 2024;29(2). doi:10.2807/1560-7917.ES.2024.29.2.2300740.
   PubMedGoogle Scholar
• Morens DM, Taubenberger JK, Fauci AS. Rethinking next-generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe. 2023;31(1):146–57. doi:10.1016/j.chom.2022.11.016.
   PubMed Web of Science ®Google Scholar
• Fauci AS, Folkers GK. Pandemic preparedness and response: lessons from COVID-19. J Infect Dis. 2023;228(4):422–5. doi:10.1093/infdis/jiad095.
   PubMed Web of Science ®Google Scholar
• Brown BD, Fauci AS, Belkaid Y, Merad M. RNA vaccines: a transformational advance. Immunity. 2023;56(12):2665–9. doi:10.1016/j.immuni.2023.11.009.
   PubMed Web of Science ®Google Scholar
• Hu L, Sun J, Wang Y, Tan D, Cao Z, Gao L, Guan Y, Jia X, Mao J. A review of inactivated COVID-19 vaccine development in China: focusing on safety and efficacy in special populations. Vaccines. 2023;11(6):11. doi:10.3390/vaccines11061045.
   Web of Science ®Google Scholar
• Heinz FX, Stiasny K. Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines. 2021;6(1):104. doi:10.1038/s41541-021-00369-6.
   PubMed Web of Science ®Google Scholar
• Cervantes-Torres J, Cabello-Gutierrez C, Ayon-Nunez DA, Soldevila G, Olguin-Alor R, Diaz G, Acero G, Segura-Velázquez R, Huerta L, Gracia-Mora I. Caveats of chimpanzee ChAdOx1 adenovirus-vectored vaccines to boost anti-SARS-CoV-2 protective immunity in mice. Appl Microbiol Biotechnol. 2024;108(1):179. doi:10.1007/s00253-023-12927-0.
   PubMed Web of Science ®Google Scholar
• Clerici B, Pontisso E, Aloise C, Peroni B, Perricone R, Pisetta C, Scavone M, Birocchi S, Podda GM. Thrombosis and bleeding in patients with vaccine-induced immune thrombotic thrombocytopenia: a systematic review of published cases. Thromb Haemost. 2023;124(5):423–31. doi:10.1055/s-0043-1777134.
   PubMedGoogle Scholar
• Jaiswal V, Mukherjee D, Peng Ang S, Kainth T, Naz S, Babu Shrestha A, Agrawal V, Mitra S, Ee Chia J, Jilma B. COVID-19 vaccine-associated myocarditis: analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature. Int J Cardiol Heart Vasc. 2023;49:101280. doi:10.1016/j.ijcha.2023.101280.
   PubMed Web of Science ®Google Scholar
• Echaide M, Chocarro de Erauso L, Bocanegra A, Blanco E, Kochan G, Escors D. Escors D. mRNA vaccines against SARS-CoV-2: advantages and caveats. Int J Mol Sci. 2023;24(6):24. doi:10.3390/ijms24065944.
   Web of Science ®Google Scholar
• Mateo-Urdiales A, Sacco C, Petrone D, Bella A, Riccardo F, Del Manso M, Bressi M, Siddu A, Brusaferro S, Palamara AT. Estimated effectiveness of a primary cycle of protein recombinant vaccine NVX-CoV2373 against COVID-19. JAMA Netw Open. 2023;6(10):e2336854. doi:10.1001/jamanetworkopen.2023.36854.
   PubMed Web of Science ®Google Scholar
• Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Lancet Respir Med. 2023;11(11):975–90. doi:10.1016/S2213-2600(23)00263-1.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang W, Chen Z, Lu S, Yang F, Bi Z, Bao L, Mo F, Li X, Huang Y. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity. Nature. 2020;586(7830):572–7. doi:10.1038/s41586-020-2599-8.
   PubMed Web of Science ®Google Scholar
• Xia X. Domains and functions of spike protein in Sars-Cov-2 in the context of vaccine design. Viruses. 2021;13(1):109. doi:10.3390/v13010109.
   PubMed Web of Science ®Google Scholar
• Hogan MJ, Pardi N. mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med. 2022;73(1):17–39. doi:10.1146/annurev-med-042420-112725.
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Anjidani N, Shahpari R, Mardani M, Sabzvari A, Yazdani B, Roshanzamir K, Bayatani B, Taheri A, Petrovsky N. Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations. Clin Microbiol Infect. 2022;28(9):1263–71. doi:10.1016/j.cmi.2022.04.004.
   PubMed Web of Science ®Google Scholar
• Bruch EM, Zhu S, Szymkowicz L, Blake T, Kiss T, James DA, Rak A, Narayan K, Balmer MT, Chicz RM. Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2. Sci Rep. 2024;14(1):2038. doi:10.1038/s41598-024-52499-1.
   PubMed Web of Science ®Google Scholar
• Pollet J, Chen W-H, Strych U. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Adv Drug Deliv Rev. 2021;170:71–82. doi:10.1016/j.addr.2021.01.001.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82(5):488–96. doi:10.1111/j.0818-9641.2004.01272.x.
   PubMed Web of Science ®Google Scholar
• Girndt M, Houser P, Manllo-Karim R, Ervin JE, Charytan C, Chow S, Symonian-Silver M, Lehrner L, Linfert D, Shemin D. Long-term immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B) compared with HepB-Eng (Engerix-B) in adults with chronic kidney disease. Vaccine. 2023;41(20):3224–32. doi:10.1016/j.vaccine.2023.04.028.
   PubMed Web of Science ®Google Scholar
• Stertman L, Palm AE, Zarnegar B, Carow B, Lunderius Andersson C, Magnusson SE, Carnrot C, Shinde V, Smith G, Glenn G. The matrix-M™ adjuvant: a critical component of vaccines for the 21 st century. Hum Vaccin Immunother. 2023;19(1):2189885. doi:10.1080/21645515.2023.2189885.
   PubMed Web of Science ®Google Scholar
• Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S. Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdox1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial. Hum Vaccin Immunother. 2023;19(1):2203632. doi:10.1080/21645515.2023.2203632.
   PubMed Web of Science ®Google Scholar
• Counoupas C, Pino P, Stella AO, Ashley C, Lukeman H, Bhattacharyya ND, Tada T, Anchisi S, Metayer C, Martinis J. High-titer neutralizing antibodies against the SARS-CoV-2 delta variant induced by alhydroxyquim-II-adjuvanted trimeric spike antigens. Microbiol Spectr. 2022;10(1):e0169521. doi:10.1128/spectrum.01695-21.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Bayas JM, Collins H, de la Pinta ML, Ledent E, Mols JF, Heineman TC. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults ≥50 years of age. J Infect Dis. 2013;208(12):1953–61. doi:10.1093/infdis/jit365.
   PubMed Web of Science ®Google Scholar
• Rts SY. RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use. Drugs Ther Perspect. 2022;38(9):373–81. doi:10.1007/s40267-022-00937-3.
   PubMedGoogle Scholar
• Girndt M, Pluer M, Dellanna F, Michelsen AK, Beige J, Toussaint K, Wehweck HJ, Koch M, Hafezi Rachti S, Faust J. Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: results of a randomized, multicenter phase 3 study. Hum Vaccin Immunother. 2022;18(6):2136912. doi:10.1080/21645515.2022.2136912.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Cooper PD. Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 2015;33(44):5920–6. doi:10.1016/j.vaccine.2015.09.030.
   PubMed Web of Science ®Google Scholar
• Thomas S, Abraham A, Baldwin J, Piplani S, Petrovsky N. Artificial Intelligence in Vaccine and Drug Design. Vaccine Design: Springer; 2022. p. 131–46.
   Google Scholar
• Görander S, Honda-Okubo Y, Bäckström M, Baldwin J, Bergström T, Petrovsky N, Liljeqvist J-Å. A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection. Vaccine. 2021;39(40):5866–75. doi:10.1016/j.vaccine.2021.08.050.
   PubMed Web of Science ®Google Scholar
• Sakala IG, Honda-Okubo Y, Li L, Baldwin J, Petrovsky N. A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization. Vaccine. 2021;39(36):5162–72. doi:10.1016/j.vaccine.2021.07.037.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Baldwin J, Petrovsky N. Advax-CpG adjuvant provides antigen dose-sparing and enhanced immunogenicity for inactivated poliomyelitis virus vaccines. Pathogens. 2021;10(5):10. doi:10.3390/pathogens10050500.
   Web of Science ®Google Scholar
• Eichinger KM, Kosanovich JL, Gidwani SV, Zomback A, Lipp MA, Perkins TN, Oury TD, Petrovsky N, Marshall CP, Yondola MA. Prefusion RSV F immunization elicits Th2-mediated lung pathology in mice when formulated with a Th2 (but not a Th1/Th2-balanced) adjuvant despite complete viral protection. Front Immunol. 2020;11:1673. doi:10.3389/fimmu.2020.01673.
   PubMed Web of Science ®Google Scholar
• Adney DR, Wang L, Van Doremalen N, Shi W, Zhang Y, Kong W-P, Miller M, Bushmaker T, Scott D, de Wit E. Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses. 2019;11(3):212. doi:10.3390/v11030212.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Barnard D, Ong CH, Peng B-H, Tseng C-T, Petrovsky N, Perlman S. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 2015;89(6):2995–3007. doi:10.1128/JVI.02980-14.
   PubMed Web of Science ®Google Scholar
• Li L, Honda-Okubo Y, Huang Y, Jang H, Carlock MA, Baldwin J, Piplani S, Bebin-Blackwell AG, Forgacs D, Sakamoto K. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine. 2021;39(40):5940–53. doi:10.1016/j.vaccine.2021.07.087.
   PubMed Web of Science ®Google Scholar
• Piplani S, Singh PK, Winkler DA, Petrovsky N. In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin. Sci Rep. 2021;11(1):13063. doi:10.1038/s41598-021-92388-5.
   PubMed Web of Science ®Google Scholar
• Baldwin J, Piplani S, Sakala IG, Honda-Okubo Y, Li L, Petrovsky N. Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis. 2021;13(24):1805–26. doi:10.4155/bio-2021-0096.
   PubMed Web of Science ®Google Scholar
• Schmidt F, Weisblum Y, Muecksch F, Hoffmann HH, Michailidis E, Lorenzi JCC, Mendoza P, Rutkowska M, Bednarski E, Gaebler C. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J Exp Med. 2020;217(11). doi:10.1084/jem.20201181.
   Web of Science ®Google Scholar
• McPherson C, Chubet R, Holtz K, Honda-Okubo Y, Barnard D, Cox M, Petrovsky N. Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant. Methods Mol Biol. 2016;1403:269–84.
   PubMedGoogle Scholar
• Silva DG, Cooper PD, Petrovsky N. Inulin-derived adjuvants efficiently promote both Th1 and Th2 immune responses. Immunol Cell Biol. 2004;82(6):611–6. doi:10.1111/j.1440-1711.2004.01290.x.
   PubMed Web of Science ®Google Scholar
• Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, Wang C, Wang Y, Li L, Ren L. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11(1):3810. doi:10.1038/s41467-020-17665-9.
   PubMed Web of Science ®Google Scholar
• Appay V, Douek DC, Price DA. CD8+ T cell efficacy in vaccination and disease. Nat Med. 2008;14(6):623–8. doi:10.1038/nm.f.1774.
   PubMed Web of Science ®Google Scholar
• Li L, Honda-Okubo Y, Baldwin J, Bowen R, Bielefeldt-Ohmann H, Petrovsky N. Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine. 2022;40(23):3182–92. doi:10.1016/j.vaccine.2022.04.041.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, Beutler N, Burns A, He WT, Limbo O, Smith C, Song G, Woehl J. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–63. doi:10.1126/science.abc7520.
   PubMed Web of Science ®Google Scholar
• Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE, Feldman J, Hauser BM, Caradonna TM, Clayton KL, Nitido AD. COVID-19-neutralizing antibodies predict disease severity and survival. Cell. 2021;184(2):476–88 e11. doi:10.1016/j.cell.2020.12.015.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Li L, Andre G, Leong KH, Howerth EW, Bebin-Blackwell AG, Ross TM, Petrovsky N. An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge. Vaccine. 2023;41(32):4710–8. doi:10.1016/j.vaccine.2023.06.063.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Bowen R, Barker M, Bielefeldt-Ohmann H, Petrovsky N. Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with beta or delta variants. Vaccine. 2023;41(48):7116–28. doi:10.1016/j.vaccine.2023.10.018.
   PubMed Web of Science ®Google Scholar
• Pal R, Ferrari MG, Honda-Okubo Y, Wattay L, Caple J, Navarrete J, Andersen H, Petrovsky N. Study of immunogenicity and efficacy against omicron BA.5 of recombinant protein-based COVID-19 vaccine delivered by intramuscular and mucosal routes in nonhuman primates. Vaccine. 2024;42(5):1122–35. doi:10.1016/j.vaccine.2024.01.034.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–93. doi:10.1038/s41590-021-01122-w.
   PubMed Web of Science ®Google Scholar
• McLelland DJ, Lynch M, Vogelnest L, Eden P, Wallace A, Weller J, Young S, Vaughan‐Higgins R, Antipov A, Honda‐Okubo Y. Safety and immunogenicity of an adjuvanted recombinant spike protein-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine,SpikeVet ™, in selected carnivora, primates and Artiodactyla in Australian zoos. J Vet Pharmacol Ther. 2024; doi:10.1111/jvp.13429.
   PubMed Web of Science ®Google Scholar
• Rabail R, Ahmed W, Ilyas M, Rajoka MSR, Hassoun A, Khalid AR, Khan MR, Aadil RM. The side effects and adverse clinical cases reported after COVID-19 immunization. Vaccines. 2022;10(4):10. doi:10.3390/vaccines10040488.
   Web of Science ®Google Scholar
• Pollard AJ, Bijker EM. A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2021;21(2):83–100. doi:10.1038/s41577-020-00479-7.
   PubMed Web of Science ®Google Scholar
• WHO. World Health Organization Target product profiles for COVID-19 vaccines. https://wwwwhoint/who-documents-detail/who-target-product-profiles-for-covid-19-vaccines2020.
   Google Scholar
• Ciolino JD, Kaizer AM, Bonner LB. Guidance on interim analysis methods in clinical trials. J Clin Transl Sci. 2023;7(1):e124. doi:10.1017/cts.2023.552.
   PubMedGoogle Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMoa2114583.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Scala A, Cavallo P, Pereira T. Measuring the efficacy of a vaccine during an epidemic. PLOS ONE. 2023;18(9):e0290652. doi:10.1371/journal.pone.0290652.
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–85. doi:10.1056/NEJMoa2113017.
   PubMed Web of Science ®Google Scholar
• Goldblatt D, Fiore-Gartland A, Johnson M, Hunt A, Bengt C, Zavadska D, Snipe HD, Brown JS, Workman L, Zar HJ. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine. 2022;40(2):306–15. doi:10.1016/j.vaccine.2021.12.006.
   PubMed Web of Science ®Google Scholar
• Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N Engl J Med. 2021;385(7):585–94. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• World Health O. Hepatitis B vaccines: WHO position paper, July 2017 – recommendations. Vaccine. 2019;37(2):223–5. doi:10.1016/j.vaccine.2017.07.046.
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, Petrovsky N, Barati S. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV-2 spike protein vaccine as a homologous and heterologous booster vaccination: a randomized placebo-controlled trial. Immunology. 2022;167(3):340–53. doi:10.1111/imm.13540.
   PubMed Web of Science ®Google Scholar
• Fendler A, Shepherd STC, Au L, Wu M, Harvey R, Schmitt AM, Tippu Z, Shum B, Farag S, Rogiers A. Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer. Lancet. 2022;399(10328):905–7. doi:10.1016/S0140-6736(22)00147-7.
   PubMed Web of Science ®Google Scholar
• Cohn BA, Cirillo PM, Murphy CC, Krigbaum NY, Wallace AW. SARS-CoV-2 vaccine protection and deaths among US veterans during 2021. Science. 2022;375(6578):331–6. doi:10.1126/science.abm0620.
   PubMed Web of Science ®Google Scholar
• Gupta D, Parthasarathy H, Sah V, Tandel D, Vedagiri D, Reddy S, Harshan KH. Inactivation of SARS-CoV-2 by beta-propiolactone causes aggregation of viral particles and loss of antigenic potential. Virus Res. 2021;305:198555. doi:10.1016/j.virusres.2021.198555.
   PubMed Web of Science ®Google Scholar
• Natarajan K, Prasad N, Dascomb K, Irving SA, Yang DH, Gaglani M, Klein NP, DeSilva MB, Ong TC, Grannis SJ. Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among Adults - VISION network, 10 states, December 2021-March 2022. Morb Mortal Wkly Rep. 2022;71(13):495–502. doi:10.15585/mmwr.mm7113e2.
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Larena M, Siddharthan V, Prow NA, Hall RA, Lobigs M, Morrey J. An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol. 2013;87(18):10324–33. doi:10.1128/JVI.00480-13.
   PubMed Web of Science ®Google Scholar
• Komiya T, Honda-Okubo Y, Baldwin J, Petrovsky N. An Advax-adjuvanted inactivated cell-culture derived Japanese encephalitis vaccine induces broadly neutralising anti-flavivirus antibodies, robust cellular immunity and provides single dose protection. Vaccines. 2021;9:1235.
   Web of Science ®Google Scholar
• Nafar M, Mostafaloo N, Firouzan A, Poorrezagholi F, Samadian F, Dalili N, Barati S, Anjidani N, Kafi H, Shahpari R. Immunogenicity and safety of SpikoGen, an adjuvanted recombinant SARS-CoV-2 Spike protein, as a heterologous third booster dose in kidney transplant patients: a Single-arm clinical trial. Clin Ther. 2022;44(12):1566–76. doi:10.1016/j.clinthera.2022.10.002.
   PubMed Web of Science ®Google Scholar
• Tabarsi P, Mamishi S, Anjidani N, Shahpari R, Kafi H, Fallah N, Yazdani B, Ebrahimi A, Roshanzamir K, Ebrahimi H. Comparative immunogenicity and safety of SpikoGen®, a recombinant SARS-CoV-2 spike protein vaccine in children and young adults: an immuno-bridging clinical trial. Int Immunopharmacol. 2024;127:111436. doi:10.1016/j.intimp.2023.111436.
   PubMed Web of Science ®Google Scholar
• Lee YK, Kwon Y, Lim D, Seo SY, Kim EK, Kim SY, Kim S, Ko M, Lim D, Seo S-Y. COVID-19 vaccine safety profile in Republic of Korea, February 26, 2021 through April 30, 2022. Clin Exp Pediatr. 2023;66(10):415–23. doi:10.3345/cep.2022.00815.
   PubMedGoogle Scholar
• Ostrowski SR, Sogaard OS, Tolstrup M, Staerke NB, Lundgren J, Ostergaard L, Hvas AM. Inflammation and platelet activation after COVID-19 vaccines - possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis. Front Immunol. 2021;12:779453. doi:10.3389/fimmu.2021.779453.
   PubMed Web of Science ®Google Scholar
• Sallard E, Zhang W, Aydin M, Schroer K, Ehrhardt A. The adenovirus vector platform: novel Insights into rational vector design and lessons learned from the COVID-19 vaccine. Viruses. 2023;15(1):15. doi:10.3390/v15010204.
   Web of Science ®Google Scholar
• Satapathy P, Kumar P, Gupta JK, Rabaan AA, Al Kaabi NA, Mohanty D, Naveen P, Khatib MN, Gaidhane S, Zahiruddin QS. The emergence and implications of SARS-CoV-2 omicron subvariant BA.2.86 on global health. Int J Surg. 2024;110(4):2498–501. doi:10.1097/JS9.0000000000001070.
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the coronavirus disease 2019 bivalent vaccine. Open Forum Infect Dis. 2023;10(6):ofad209. doi:10.1093/ofid/ofad209.
   PubMed Web of Science ®Google Scholar
• Mostaghimi D, Valdez CN, Larson HT, Kalinich CC, Iwasaki A. Prevention of host-to-host transmission by SARS-CoV-2 vaccines. Lancet Infect Dis. 2022;22(2):52–8. doi:10.1016/S1473-3099(21)00472-2.
   Web of Science ®Google Scholar
• Staerke NB, Reekie J, Nielsen H, Benfield T, Wiese L, Knudsen LS, Iversen MB, Iversen K, Fogh K, Bodilsen J. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with delta or omicron variant breakthrough infections. Nat Commun. 2022;13(1):4466. doi:10.1038/s41467-022-32254-8.
   PubMed Web of Science ®Google Scholar
• Hui DS. Hybrid immunity and strategies for COVID-19 vaccination. Lancet Infect Dis. 2023;23(1):2–3. doi:10.1016/S1473-3099(22)00640-5.
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Burke PC, Nowacki AS, Gordon SM, Acuti Martellucci C. Risk of coronavirus disease 2019 (COVID-19) among those up-to-date and not up-to-date on COVID-19 vaccination by US CDC criteria. PLOS ONE. 2023;18(11):e0293449. doi:10.1371/journal.pone.0293449.
   PubMed Web of Science ®Google Scholar
• Sajkov D, Woodman R, Honda-Okubo Y, Barbara J, Chew D, Toson B, Petrovsky N. A multi-season randomised controlled trial of Advax-adjuvanted seasonal influenza vaccine in participants with chronic disease or older age. J Infect Dis. 2023; doi:10.1093/infdis/jiad589.
   PubMedGoogle Scholar
• Akhtar M, Islam MR, Khaton F, Soltana UH, Jafrin SA, Rahman SIA, Tauheed I, Ahmed T, Khan II, Akter A. Appearance of tolerance-induction and non-inflammatory SARS-CoV-2 spike-specific IgG4 antibodies after COVID-19 booster vaccinations. Front Immunol. 2023;14:1309997. doi:10.3389/fimmu.2023.1309997.
   PubMed Web of Science ®Google Scholar
• Boretti A. mRNA vaccine boosters and impaired immune system response in immune compromised individuals: a narrative review. Clin Exp Med. 2024;24(1):23. doi:10.1007/s10238-023-01264-1.
   PubMed Web of Science ®Google Scholar